COVID-19：富士フイルム､中国でアビガン販売：Carelinkと提携（動画）：
COVID-19: Fujifilm sells Avigan in China: partner with Carelink：
COVID-19：Fujifilm在中国出售Avigan：与Carelink合作
COVID-19：
「アビガン」の中国展開に向け、パートナー企業にCarelink社を、選定しました。
富士フイルム富山化学：
Carelink社と、輸入医薬品承認の申請代理権を独占的に与える覚書を締結。
安徽康レイ薬業：（Carelink）
Shanghai-based Carelink Pharmaceutical Co.
富士フイルム富山化学が、これまで蓄積してきた「アビガン」のデータを活用します。
ー非臨床・臨床データ（対象：インフルエンザ・新型コロナウイルス感染症）ー
今後、輸入医薬品承認に向けた申請業務を行う計画です。
アビガン注射剤を開発：
富士フイルム富山化学は、「アビガン」による治療選択肢を広げます。
Carelink社と共同で注射剤の開発を行っていきます。
富士フイルム [日本]
https://www.fujifilm.com/jp/ja/news/list/5590
Fujifilm Partners with Chinese Pharmaceutical Company Carelink in Deploying Anti-influenza Drug Avigan® Tablets in China
TOKYO, October 22, 2020
FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada)
has announced that the company has partnered with Chinese pharmaceutical company Carelink Pharmaceutical Co., Ltd. (hereinafter “Carelink”) in deploying anti-influenza drug Avigan® Tablets (generic name: favipiravir,“Avigan”) in China.
Going forward, through a future application and approval of Avigan for imported drug registration,
to be submitted by Carelink, FUJIFILM Toyama Chemical aims to introduce Avigan to the Chinese market.
Carelink
is a pharmaceutical company that is actively engaged in developing new drugs by making use of their staff that have ample global experiences in Japan, Asia, Europe and the U.S.,
as well as extensive clinical development expertise and track records, with the aim of broadly supplying high-quality pharmaceuticals not only in China but to the entire world.
At present, Carelink
has expanded its area of development to infectious diseases as well as lifestyle diseases, and is working to develop antiviral drugs.
In addition, with pharmaceuticals that have already been approved in Europe and the U.S., the company collaborates with partner corporations both inside and outside China to promote clinical drug development and submit applications for their approval as imported drugs.
Fujifilm Japan
https://www.fujifilm.com/jp/en/news/hq/5590
Fujifilm works with Shanghai firm Carelink to get Avigan approved in China
Carelink
will use Fujifilm’s data on Avigan’s treatment of novel coronavirus infections and influenza to seek imported drug approval in China,Fujifilm said in a statement.
The two companies also plan to develop an injectable form of the drug.Fujifilm said last week
it was seeking approval for Avigan as a treatment for COVID-19 in Japan.That followed results from a late-stage study in Japan
that showed the antiviral drug reduced recovery time for patients with nonsevere symptoms.
Avigan,
originally developed as an emergency flu drug andknown generically worldwide as favipiravir, has been approved in India and Russia to treat COVID-19.
late-stage study of COVID-19 in Japan
Last month, Fujifilm
said the late-stage study of 156 COVID-19 patients in Japan showedthat symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.
Results of the study,
conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant.The Japan Times